Open Orphan awarded a contract for a study with Oxford BioTherapeutics

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced its subsidiary Venn Life Sciences has been awarded a contract for a study with Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immune-oncology and antibody-drug conjugate-based therapies.

This is a phase I, open-label, dose finding study which will be used to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in recurrent and/or metastatic CD205-positive solid tumours and in women with CD205-positive HER2-negative metastatic breast cancer.

For this study, the Venn Paris team will deliver high-quality data management and statistics services. Venn’s team in Paris are highly regarded in the field as one of the leading providers in this area which is a perfect complement to the Company’s London offering. The study is due to start immediately.

Dr Rahim Fandi, MD, PhD Oxford BioTherapeutics CMO commented: “We are delighted to work with Venn and are sure that Oxford BioTherapeutics will benefit from their expertise.”

Cathal Friel, Executive Chairman, Open Orphan, commented: “We are delighted to be in a position to announce another contract win for the Paris team. This deal further demonstrates Open Orphan’s ability to execute on its significant pipeline of contracts with important pharmaceutical businesses.

“Oxford BioTherapeutics is a clinical stage oncology company with a pipeline of first-in-class therapies aiming to fulfil major unmet patient needs by targeting difficult-to-treat cancers. The Venn team are looking forward to assisting with the study and providing the preliminary data required to advance this breast cancer trial.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Open Orphan considers spinning out assets

Specialist pharmaceutical services clinical research company, Open Orphan, is considering a possible spin-out of certain non-core development intellectual property assets. The company said the potential demerger is at an advanced stage of planning. The assets include HVO-001, a

Open Orphan Plc

Open Orphan plans for possible spin out of non-core assets

Dublin-listed pharmaceutical services company Open Orphan said it is planning for a possible spin-out of some of its non-core development intellectual property assets. The company said it believed the assets in question were best developed separately from the core services

Open Orphan Plc

Open Orphan monetisation of some of non-core assets

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that it is at an advanced stage in planning for a

Open Orphan Plc

Open Orphan’s hVIVO launches its Disease in Motion platform

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, has officially launched its Disease in

Open Orphan Plc

First volunteers on COVID-19 human challenge study leave quarantine

The UK’s COVID-19 human challenge study has reached its first milestone after administering virus to three volunteers in a controlled clinical setting The first participants recruited to the landmark trial have now completed a period of quarantine at the Royal Free Hospital

Open Orphan Plc

Cathal Friel’s Open Orphan mulls Imutex cash-in

Speculation is mounting that Open Orphan, a clinical trial company headed by Irish dealmaker Cathal Friel, will move to spin off its stake in vaccine developer Imutex via a Nasdaq listing this year. Through its hVivo subsidiary, Open Orphan holds

Open Orphan Plc

Open Orphan subsidiary wins €7.5m contract to run study

Dublin-listed pharmaceutical services company Open Orphan’s subsidiary Hvivo has won a contract worth €7.5 million to run a human viral challenge study. Open Orphan, a European-focused, rare and orphan drug consulting services platform, is the result of executive chairman Cathal Friel reversing

Open Orphan Plc

Open Orphan’s hVIVO secures £7.5m RSV Human Challenge Study contract

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, has entered into a contract